The comparative analysis of observation of two patient group (I group included the children received no Enterosgel (control) and II group included the children whose therapy involved this drug) showed that the improvement of the main clinical implications of disease (DRS) was diagnosed in the children received Enterosgel as a part of the complex therapy: in 75% of patients, the rash elements decreased in Day 3-4 after drug administration and Quicke's edema disappeared in Day 2-3 of treatment. The positive effect of the Enterosgel therapy on the dyspeptic syndrome was observed: stool was normalizaed and nausea was terminated. In 49% of patients, disappearance of the pain abdominal syndrome was noted. It should be said that, in children under 2 years, the improvement in the decrement of the main disease manifestations was less appreciable and more delayed. This is explained by the morphofunctional dismaturity of the gastrointestinal tract in children of this age (enzymatic and topical immunologic deficiency, late onset of the formation of intestinal microbiology). At the same time, in the control group children received no Enterosgel, the improvement of clinical signs of DRS was less considerable and diagnosed only in 22% of patients. Disappearance of the DRS syndromes, pain abdominal and dyspeptic syndromes was delayed up to 7-8 Day of the complex therapy.
Thus, based on the study performed, one can conclude that application of Enterosgel in the complex therapy of childhood allergic diseases is pathogenetically proved and reasonable.